(Press-News.org) At Moffitt Cancer Center, patients with stage III and IV unresectable melanoma are now routinely genetically profiled for several gene mutations, including the BRAF gene, a known driver oncogene for melanoma. Research has shown that mutations in the BRAF gene determine sensitivity or resistance to a class of drugs that are BRAF inhibitors.
"We have found that a large number of patients with melanoma who have the BRAF gene mutation quickly develop resistance to drugs that are BRAF inhibitors," said Jeffrey S. Weber, M.D., Ph.D., director of the Donald A. Adam Comprehensive Melanoma Research Center at Moffitt. "A recent approach in the melanoma research community is to find ways to overcome resistance to drugs we targeted to mutated BRAF."
At Moffitt, researchers have access to a large database of patient-donated tissues through Moffitt's Total Cancer Care™ program, a far-reaching design for care that includes building a biorepository of tumor samples for study and patient selection for clinical trials participation. By looking for patient genetic profiles for BRAF, Moffitt researchers are working at the frontiers of personalized medicine, which is the effort to match the right patient to the right drug.
According to Weber, although 50 percent of melanoma patients might have the BRAF mutation, the lack of other valid molecular targets for melanoma has "hampered efforts to individualize therapy."
That may have changed now that the U.S. Food and Drug Administration approved the drug Vemurafenib for melanoma patients who test positive for the BRAF mutation.
An international team of researchers, including those at Moffitt led by Weber, found that when tested in a phase II clinical trial, Vemurafenib was highly effective for patients with previously treated metastatic melanoma that had the BRAF mutation.
The study was published in a recent issue of The New England Journal of Medicine (366;8).
However, Moffitt researchers know that patients can develop resistance to Vemurafenib and, consequently tested six different models of Vemurafenib resistance against an "inhibitor" called XL888. Their findings appeared in a recent issue of Clinical Cancer Research, a publication of the American Association for Cancer Research.
"We found that the inhibitor XL888 overcomes Vemurafenib resistance through a number of mechanisms," said Keiran S. Smalley, Ph.D., of Moffitt' s Departments of Molecular Oncology and Cutaneous Oncology and who is a colleague of Weber and the senior author on the study.
According to Smalley, there was already evidence that one of a family of inhibitors called HSP90 could overcome multiple drug chemotherapy resistance mechanisms in a number of cancers, including non-small cell lung cancer and breast cancer. They hoped it would help arrest the cancer cell cycle in melanoma cell lines resistant to the BRAF inhibitors.
"Responses to XL888 were highly durable, with no resistant colonies emerging after four weeks of treatment," Smalley said. "In control studies not using XL888, resistant colonies emerged in every case."
For Weber, the success of Vemurafenib represents "the single most dramatic improvement in the treatment of melanoma in 20 years."
"The 53 percent response rate on the Vemurafenib study for previously treated melanoma patients with the BRAF mutation was significantly better than response rates seen in studies of other therapies for melanoma," Weber said. "To be able to find a mutation through gene profiling and develop a test to match a patient to the best treatment for them is the kind of personalized medicine we want to be known for at Moffitt."
INFORMATION:
About Moffitt Cancer Center
Follow Moffitt on Facebook: www.facebook.com/MoffittCancerCenter
Follow Moffitt on Twitter: @MoffittNews
Follow Moffitt on YouTube: MoffittNews
Located in Tampa, Moffitt Cancer Center is a National Cancer Institute-designated Comprehensive Cancer Center, which recognizes Moffitt's excellence in research and contributions to clinical trials, prevention and cancer control. Moffitt is also a member of the National Comprehensive Cancer Network, a prestigious alliance of the country's leading cancer centers, and is listed in U.S. News & World Report as one of "America's Best Hospitals" for cancer.
Media release by Florida Science Communications
END
Researchers at Moffitt Cancer Center have placed new emphasis on gathering data on cancer patient quality of life during both treatment and survivorship. Their focus is on gathering and using that data to develop interventions to improve the quality of life for patients in treatment and for cancer survivors.
Much of the quality of life and survivorship research is carried out by researchers in Moffitt's Department of Health Outcomes & Behavior.
"Among the several research goals of the Department of Health Outcomes & Behaviors is the evaluation and improvement of quality ...
A new study from researchers at the Bangkok Breast Center shows significant improvement in the detection of breast cancer in Asian women using automated breast volume sonography (ABVS) as compared to hand-held ultrasound (HHUS).
In their study on 504 findings in 212 patients at the Bangkok Breast Center, researchers found that ABVS agreed with HHUS in detecting 15 suspicious lesions, uncovered 12 additional suspicious lesions, and excluded 3 suspicious lesions in these cases. A coordinating five-year retrospective study on 26,741 mammograms with ultrasound also revealed ...
As skiing and snowboarding continue to be the most popular winter sports, they also carry a significant risk of injury. One new exhibit will show how radiologists can meet these injuries head on with proper patient management and the latest imaging techniques.
"It is important for radiologists to understand these injuries patterns," said Dr. Hillary Boortz, lead author for this exhibit. "When a patient presents with the appropriate history, the radiologist can properly protocol the study and alter their search algorithms to assure that an injury isn't overlooked." She ...
As more patients are referred to tertiary care center with previous images, a new study from researchers at the Westchester Medical Center shows how radiologists are tackling the challenges of interpreting outside studies and reviewing discordance opinions.
"Outside studies were becoming a problem in our institution," said Dr. Zvi Lefkovitz, co-lead for this study. "We were receiving a lot of disjointed, fly-by-night examinations, and we had no formalized policy for reviewing these exams." Lefkovitz and his team began a comprehensive process of overhauling their procedures, ...
Shoulder injuries are among the most frequently encountered musculoskeletal injuries treated in emergency departments. One new study shows how radiologists can more effectively identify these injuries and improve patient outcomes.
"The severity of shoulder injuries are often underestimated," said Dr. Scott Sheehan, lead author for the study. "Subtle injuries can have significant consequences if not recognized and treated promptly." Sheehan and his co-authors began studying the effects of traumatic shoulder injuries after one of his radiology mentors suffered a shoulder ...
A new study from UCLA shows how magnetic resonance angiography (MRA) and computed tomography angiography (CTA) are equivalent in delineating anatomy in living renal donors.
In a study that examined 30 patients and 60 kidneys, both modalities were "excellent" in detecting the number of renal arteries and veins. Dr. Mittul Gulati, lead author for the study noted, "either MRA or CTA are great tools for helping surgeons remove kidneys safely, identifying donor and recipient veins and vessels, and identifying incidental findings."
The results could potentially reduce radiation ...
With the increase of obesity in the last 50 years, bariatric surgeries are becoming a common solution for tackling this epidemic. A new exhibit shows how radiologists play a key role in ensuring the success of these procedures.
"Although complications are generally rare with Roux-en-Y gastric bypass and gastric banding procedures, it's critical for radiologists to be familiar with both the normal presentations and possible complications for these surgeries," said Dr. Mariam Moshiri, lead author for this presentation.
Dr. Moshiri and her co-authors at the University ...
VIDEO:
This is Fahd A. Ahmad, M.D. of Washington University School of Medicine in St. Louis.
Click here for more information.
BOSTON – More than 1 million youths ages 15-24 have sexually transmitted infections (STIs) caused by Chlamydia trachomatis and Neisseria gonorrhea. Many others, however, are unaware they are infected because they have not been tested.
Technology can change that, according to preliminary data from a study to be presented Saturday, April 28, at the Pediatric ...
BOSTON – Although children are more likely than adults to suffer from many diseases, few clinical trials are being conducted to test drugs in pediatric patients, according to a study to be presented Saturday, April 28, at the Pediatric Academic Societies (PAS) annual meeting in Boston.
Drug studies in children are important because children often respond differently to medications than adults. However, there is widespread concern about the lack of clinical evidence available to guide physicians in prescribing pharmaceuticals to children.
Florence Bourgeois, MD, MPH, ...
BOSTON – Contrary to what many trauma teams believe, the presence of family members does not impede the care of injured children in the emergency department, according to a study to be presented Saturday, April 28, at the Pediatric Academic Societies (PAS) annual meeting in Boston.
Professional medical societies, including the American Academy of Pediatrics and the American College of Emergency Physicians, support family presence during resuscitations and invasive procedures. The degree of family member involvement ranges from observation to participation, depending ...
